sarepta gene therapy - Search News

Order byBest matchMost fresh

Sarepta reports 2nd patient death

Top News

Impacts

Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy

A second patient receiving its experimental gene therapy Elevidys has died from liver failure, raising serious questions on the drug’s outlook.

· 19h · on MSN

Second patient death reported with gene therapy for muscular dystrophy

· 22h

Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio cream

· 1d

Sarepta shares crash as second patient dies after receiving its gene therapy

U.S. consumer prices rose slightly in May as gasoline prices remained subdued, but inflation is likely to pick up in the months as tariffs boost the cost of imported goods.

· 1d

Sarepta crashes after second death linked to Roche-partnered Elevidys

· 1d

Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom

Sarepta Therapeutics (NasdaqGS:SRPT) SRP-9003 Gene Therapy Earns FDA Platform Technology Designation

Sarepta Therapeutics (NasdaqGS:SRPT) recently announced that its SRP-9003 gene therapy received a platform technology designation from the FDA, and updated safety protocols for ELEVIDYS in the UK. Despite these developments,

STAT1d

After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other parents still push for the therapy.

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy,

BioPharma Dive6d

SpliceBio lands $135M for a new kind of eye gene therapy

The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to help overcome the packaging constraints of current genetic medicines.

BioSpace6d

As Gene Therapy Endures ‘Cold Winter,’ FDA Leaders Promise Support

Gene therapies have ridden investor mania to huge valuations but commercialization challenges have pushed market caps to the floor. At an FDA roundtable last week, FDA leaders promised faster approvals and broad support to the industry.

Explore more

Duchenne muscular dystrophy

Elevidys